Table 2. Proportion of patients with ocular and non-ocular AEs in treatment-naïve and prior ranibizumab-treated patients with mCNV at 1 year.

Preferred term, n (%)	Treatment-naïve, n = 108	Prior ranibizumab-treated, n = 175
Ocular AEs, total	11 (10.19)	18 (10.29)
Increased IOP	2 (1.85)	2 (1.14)
Cataract	1 (0.93)	2 (1.14)
Glaucoma	0	3 (1.71)
Visual acuity reduced	1 (0.93)	2 (1.14)
Conjunctival hemorrhage	0	2 (1.14)
Non-ocular AEs, total	11 (10.19)	23 (13.14)
Depression	0	4 (2.29)
Nasopharyngitis	0	2 (1.14)
Fall	0	2 (1.14)
Localized infection	0	2 (1.14)
Pulmonary fibrosis	0	2 (1.14)

Indication and pre-treatment status refers to the primary treated eye. Only AEs occurring during the safety observation period are included. Preferred terms are presented by descending order of frequency in the total column. A patient with multiple occurrences of an AE was counted once per preferred term. A patient with multiple AEs is counted only once in the total row. Patients with a baseline visit date present are included. Data collected until the last recorded follow-up date was used to perform the analyses. Ocular and non-ocular AEs >2 in number are shown.

AE, adverse events; IOP, intraocular pressure; mCNV, myopic choroidal neovascularization; n, number of patients; VA, visual acuity.